Improved prognosis in soft-tissue sarcoma of extremity and trunk wall: Comparison of patients diagnosed during 1998–2001 and 2005–2010 in Finland

Autor: Mika M Sampo, Katariina Klintrup, Erkki J Tukiainen, Tom O Böhling, Carl P Blomqvist

Publikováno v: Acta Orthopaedica, Vol 88, Iss 1, Pp 116-120 (2017)

Background and purpose — Soft-tissue sarcoma (STS) is rare, with challenging individualized treatment, so diagnostics and treatment should be centralized. Historical controls are sometimes used for investigation of whether new diagnostic or therape

Externí odkaz: https://doaj.org/article/a5841b1f17e4436a8036920b8009f4c2

Local relapse of soft tissue sarcoma of the extremities or trunk wall operated on with wide margins without radiation therapy

Autor: Jasmiini Lemma, Sari Jäämaa, Jussi P Repo, Kirsi Santti, Juho Salo, Carl P Blomqvist, Mika M Sampo

Publikováno v: BJS Open. 7

Background The quality of surgical margins is the most important factor affecting local control in soft tissue sarcoma (STS). Despite this, there is no universally accepted consensus on the definition of an adequate surgical margin or on which patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7807cc8799ddae6c854415b22265c7b0
https://doi.org/10.1093/bjsopen/zrac172

A Retrospective Analysis of Systemic Oncologic Treatment in Older Patients With Advanced Soft-tissue Sarcoma.

Autor: Lemma J; Comprehensive Cancer Center, Helsinki University Hospital (HUH), Helsinki, Finland and University of Helsinki, Helsinki, Finland., Liljeström J; The University of Helsinki, Helsinki, Finland., Sampo M; Comprehensive Cancer Center, Helsinki University Hospital (HUH), Helsinki, Finland and University of Helsinki, Helsinki, Finland.; HUSLAB Pathology and University of Helsinki, Helsinki, Finland., Nevala R; Comprehensive Cancer Center, Helsinki University Hospital (HUH), Helsinki, Finland and University of Helsinki, Helsinki, Finland., Blomqvist C; Comprehensive Cancer Center, Helsinki University Hospital (HUH), Helsinki, Finland and University of Helsinki, Helsinki, Finland., Elmegiri M; The University of Helsinki, Helsinki, Finland.; Department of Radiology, Medical Imaging Center, Helsinki, Finland., Jäämaa S; Comprehensive Cancer Center, Helsinki University Hospital (HUH), Helsinki, Finland and University of Helsinki, Helsinki, Finland; sari.jaamaa@hus.fi.

Publikováno v: Anticancer research [Anticancer Res] 2024 Jul; Vol. 44 (7), pp. 3067-3075.

PDE3A Is a Highly Expressed Therapy Target in Myxoid Liposarcoma.

Autor: Toivanen K; Department of Pathology, Helsinki University Hospital, University of Helsinki, 00014 Helsinki, Finland., Kilpinen S; Molecular and Integrative Biosciences Research Programme, University of Helsinki, 00014 Helsinki, Finland., Ojala K; HUS Vatsakeskus, Helsinki University Hospital, PL 340, 00290 Helsinki, Finland., Merikoski N; Department of Pathology, Helsinki University Hospital, University of Helsinki, 00014 Helsinki, Finland., Salmikangas S; Department of Pathology, Helsinki University Hospital, University of Helsinki, 00014 Helsinki, Finland., Sampo M; Department of Pathology, HUSLAB, HUS Diagnostic Center, Helsinki University Hospital, University of Helsinki, 00029 Helsinki, Finland., Böhling T; Department of Pathology, Helsinki University Hospital, University of Helsinki, 00014 Helsinki, Finland., Sihto H; Department of Pathology, Helsinki University Hospital, University of Helsinki, 00014 Helsinki, Finland.

Publikováno v: Cancers [Cancers (Basel)] 2023 Nov 07; Vol. 15 (22). Date of Electronic Publication: 2023 Nov 07.

PROX1 transcription factor controls rhabdomyosarcoma growth, stemness, myogenic properties and therapeutic targets.

Autor: Gizaw NY; Stem Cells and Metabolism Research Program, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki 00014, Finland., Kallio P; Translational Cancer Medicine Program and iCAN Digital Precision Cancer Medicine Flagship, Faculty of Medicine, University of Helsinki, Helsinki 00014, Finland., Punger T; Stem Cells and Metabolism Research Program, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki 00014, Finland., Gucciardo E; Individualized Drug Therapy Research Program, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki 00290, Finland., Haglund C; Translational Cancer Medicine Program and iCAN Digital Precision Cancer Medicine Flagship, Faculty of Medicine, University of Helsinki, Helsinki 00014, Finland.; Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki 00014, Finland.; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki 00014, Finland., Böhling T; Department of Pathology, University of Helsinki, Helsinki 00014, Finland., Lehti K; Individualized Drug Therapy Research Program, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki 00290, Finland.; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Solna 17165, Sweden.; Department of Biomedical Laboratory Science, Norwegian University of Science and Technology (NTNU), Trondheim 7491, Norway., Sampo M; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki 00014, Finland., Alitalo K; Translational Cancer Medicine Program and iCAN Digital Precision Cancer Medicine Flagship, Faculty of Medicine, University of Helsinki, Helsinki 00014, Finland.; Wihuri Research Institute, Helsinki 00290, Finland., Kivelä R; Stem Cells and Metabolism Research Program, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki 00014, Finland.; Wihuri Research Institute, Helsinki 00290, Finland.; Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä 40700, Finland.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2022 Dec 06; Vol. 119 (49), pp. e2116220119. Date of Electronic Publication: 2022 Dec 02.